Ligand Pharmaceuticals (LGND) to Release Quarterly Earnings on Thursday

Ligand Pharmaceuticals (NASDAQ:LGND) is expected to be posting its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of $1.84 per share and revenue of $61.4050 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Ligand Pharmaceuticals (NASDAQ:LGND) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $1.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.84 by ($0.21). The business had revenue of $51.72 million for the quarter, compared to analysts’ expectations of $59.10 million. Ligand Pharmaceuticals had a return on equity of 16.19% and a net margin of 55.95%.The company’s revenue for the quarter was up 14.1% on a year-over-year basis. During the same period in the previous year, the business posted $1.33 earnings per share. On average, analysts expect Ligand Pharmaceuticals to post $5 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Ligand Pharmaceuticals Trading Down 2.8%

NASDAQ LGND opened at $288.01 on Thursday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 20.95 and a current ratio of 21.28. The firm has a market cap of $5.77 billion, a PE ratio of 39.08, a P/E/G ratio of 2.93 and a beta of 1.10. Ligand Pharmaceuticals has a one year low of $129.55 and a one year high of $326.63. The firm’s fifty day moving average is $276.89 and its two-hundred day moving average is $230.73.

Analyst Ratings Changes

LGND has been the subject of several recent research reports. Stifel Nicolaus increased their target price on shares of Ligand Pharmaceuticals from $255.00 to $332.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Citigroup began coverage on Ligand Pharmaceuticals in a research report on Tuesday, July 21st. They issued a “buy” rating and a $387.00 price target on the stock. HC Wainwright upped their price objective on Ligand Pharmaceuticals from $243.00 to $289.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Bank of America increased their price objective on Ligand Pharmaceuticals from $266.00 to $388.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th. Finally, Weiss Ratings cut Ligand Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Seven analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $319.00.

Insider Buying and Selling

In other Ligand Pharmaceuticals news, Director Jason Aryeh sold 4,500 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $250.00, for a total transaction of $1,125,000.00. Following the completion of the transaction, the director owned 102,580 shares in the company, valued at approximately $25,645,000. This represents a 4.20% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Andrew Reardon sold 5,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $313.28, for a total transaction of $1,566,400.00. Following the transaction, the insider owned 41,514 shares of the company’s stock, valued at approximately $13,005,505.92. The trade was a 10.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 35,698 shares of company stock worth $9,019,252 in the last ninety days. Insiders own 5.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in LGND. Royal Bank of Canada boosted its holdings in Ligand Pharmaceuticals by 25.8% in the 1st quarter. Royal Bank of Canada now owns 6,120 shares of the biotechnology company’s stock valued at $644,000 after purchasing an additional 1,256 shares in the last quarter. AQR Capital Management LLC acquired a new position in Ligand Pharmaceuticals during the 1st quarter worth approximately $344,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Ligand Pharmaceuticals by 8.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,660 shares of the biotechnology company’s stock worth $1,121,000 after purchasing an additional 809 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Ligand Pharmaceuticals by 9.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 55,327 shares of the biotechnology company’s stock worth $5,817,000 after buying an additional 4,926 shares in the last quarter. Finally, Jane Street Group LLC raised its stake in shares of Ligand Pharmaceuticals by 176.2% during the 1st quarter. Jane Street Group LLC now owns 36,922 shares of the biotechnology company’s stock worth $3,882,000 after buying an additional 23,553 shares in the last quarter. 91.28% of the stock is owned by hedge funds and other institutional investors.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms.